Cinqüenta anos demedicamentosantipsicóticos empsiquiatria

Cinqüenta anos demedicamentosantipsicóticos empsiquiatria

(Parte 6 de 10)

CLORIDRATO DE PROMETAZINA (Instituto Biochimico) - comp. cx. c/20 e 200 de 25mg; amp. cx. c/50 e 100 de 2ml c/50mg cada. Instituto Biochimico Ltda. Rua Luigi Galvani 70 7 andar (04575020) São Paulo, SÃO PAULO. (011) 5505- 3536, (011) 5505-3540.

PROMETAZINA (EMS) - clorid., sol. inj. amp. c/50 e 100 de 2ml. Comp. revest. cx. c/20. EMS Ind. Farmacêutica Ltda. Rua Com. Carlo Mario Gardano 450 (09720470) S.B. do Campo, SÃO PAULO. (011) 448-1677 R.1056, (011) 448-1297. No Exterior:

Fenotiazina, 10-(3-(dimetilamino)propil)-2- (trifluorometil)- ou: 10-[3-dimetilamino-propil]-2-trifluorometilfenotiazina ou: 10H-Fenotiazina-10-propanamina, N,N-dimetil-2- (trifluorometil)- ou:

N,N-Dimetil-2-(trifluorometil)-10H-fenotiazina- 10-propanamina ou: (SKF 4648) (MC 4703) (NSC 14959) (NSC 17473) (HSDB 3407),

(CAS RN 146-54-3, base), (CAS RN 1098-60-8, cloridrato).

FM: C18-H19-F3-N2-S.Cl-H D: 20 a 150mg. (73, 143); 20 a 200mg. (07); 50

Antipsicótico de potência intermediária.

Na molécula da clorpromazina, o átomo de cloro é substituído por um grupo trifluorometila, o que acentua o efeito sedativo em 2 a 3 vezes. Introduzida na década de 60 e substituída em grande parte pela levomepromazina, seu uso se limitou à medicina geral como pré-anestésico e antiemético. Nesta última indicação, mostrou-se uma opção inferior à metoclopramida tanto em eficácia quanto em tolerabilidade (134). Tem os mesmos efeitos cardiocirculatórios da clorpromazina com maior propensão a sintomas extrapiramidais. Como a prometazina, tem sido usada também como medicação sedativa antes e durante o trabalho de parto. Seu efeito in vitro anti-Trypanosoma cruzi, juntamente com o da clorpromazina, foi experimentalmente confirmado por pesquisadores do Instituto Oswaldo Cruz (FIOCRUZ) em Manguinhos, Rio de Janeiro, muito embora seu aproveitamento seja limitado pela citotoxicidade das doses necessárias para observação do efeito (34).

Não disponível comercialmente no Brasil

No Exterior:

Referências Bibliográficas (Fenotiazinas Alifáticas):

Vannucchi AM, Fanci R, Rossi-Ferrini POndansetron

01. Abe S, Suzuki T, Hori T, Baba A, Shiraishi H. Hypogammaglobulinemia during antipsychotic therapy. Psychiatry Clin Neurosci 1998; 52(1):115-7. 02. Akintonwa DA. A new concept in the relationship between biochemical reaction mechanisms and molecular basis of agranulocytosis. Biochem Med 1984; 32(2):151-60. 03. Ananth JV, Lehmann HE, Ban TA. Agranulocytosis associated with methotrimeprazine (Nozinan) administration: a report of three cases. Can Med Assoc J 1970; 102(12):1286- 7. 04. Angelini G, Vena GA, Meneghini CL. Allergic contact dermatitis to some medicaments. Contact Dermatitis 1985; 12(5):263-9. 05. Avis SP, Holzbecher MD. A fatal case of methotrimeprazine overdose. J Forensic Sci 1996; 41(6):1080- 1. 06. Baldo BA, Harle DG, Fisher M. In vitro diagnosis and studies on the mechanism(s) of anaphylactoid reactions to muscle relaxant drugs. Ann Fr Anesth Reanim 1985; 4(2):139- 45. 07. Benkert O & Hippius H. Farmacoterapia Psiquiatrica. Trad Esp 3 ed alemã, EUNSA, Pamplona, 1981. 08. Bergman J, Wallman P. Promethazine overdose: is it a "Goodnight" after all? N Z Med J 1998; 1(1069):246-8. 09. Bertini R, Garattini S, Delgado R, Ghezzi P. Pharmacological activities of chlorpromazine involved in the inhibition of tumour necrosis factor production in vivo in mice. Immunology 1993 Jun;79(2):217-9. 10. Bloom D, Krishnan B, Thavundayil JX, Lal S. Resolution of chlorpromazine-induced cutaneous pigmentation following substitution with levomepromazine or other neuroleptics. ActaPsychiatr Scand 1993; 87(3):223-4. 1. Bosi A, Guidi S, Messori A, Saccardi R, Lombardini L, versus chlorpromazine for preventing emesis in bone marrow transplant recipients: a double-blind randomized study. J Chemother 1993; 5(3):191-6. 12. Bourgeois M. Priapisms during neuroleptic drug administration (3 cases).Nouv Presse Med 1972; 1(17):1161. 13. Cadranel JF, Bonnard P, Cazier A, di Martino V, Pras V, Devergie B, Biour M . Cyamamezine-induced acute hepatitis after unique massive intake: a case report. Eur J Gastroenterol Hepatol 1999; 1(4):451-3. 14. Cahane M, Chen V, Avni I. Persistent chlorpromazine deposits in donor corneal tissue after corneal transplantation. Cornea 1997; 16(5):588-9. 15. Caldwell AE. Historia de la Psicofarmacologia. In: Clark WG & del Giudice J. Principios De Psicofarmacologia. Trad esp, La Prensa Medica Mexicana, Mexico, 1975. 16. Campos JS et al. Algumas observações sobre o emprego da Rauwolfia sello “wu” em psiquiatria. Bol Inst Vital Brasil 1954; 5:199. 17. Castro SL, Soeiro MN, De Meirelles M de N. Trypanosoma cruzi: effect of phenothiazines on the parasite and its interaction with host cells. Mem Inst Oswaldo Cruz 1992; 87(2):209-15.

chemidplus/cmplxqry.html
1981; 74(2):101-4

18. Chambers FA, O'Leary E, Gormley PK, Flynn NM. Delayed profound respiratory depression after premedication with trimeprazine. Anaesthesia 1992; 47(7):585-6. 19. Chan BS, Graudins A, Whyte IM, Dawson AH, Braitberg G & Duggin G. Serotonin syndrome resulting from drug interactions. Med J Aust 1998; 169(10):523-5. 20. Chan C, Yin H, Garforth J, McKie JH, Jaouhari R, Speers P, Douglas KT, Rock PJ, Yardley V, Croft SL, Fairlamb AH. Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs. J Med Chem 1998; 41(2):148-56. 21. Chan-Tack KM. Neuroleptic malignant syndrome due to promethazine. South Med J 1999; 92(10):1017-8. 2. CHEMIDPLUS DATABASE. Disponível em: http://chem.sis.nlm.nih.gov/ 23. Chetty M, Gouws E, Miller R & Moodley SV. The use of a side effect as a qualitative indicator of phlasma chlorpromazine levels. Eur Neuropsychopharmacol 1999; 9(1- 2):7-82. 24. Ciraulo DA, Shader RI, Greenblatt DJ & Creelman W. Drug interactions in psychiatry. 2 ed, Williams & Wilkins, Baltimore, 1995. 25. Clark WG & del Giudice J. Principios De Psicofarmacologia. Trad esp, La Prensa Medica Mexicana, Mexico, 1975. 26. Conley R, Tamminga CA, Bartko J, Richardson C, Peszke M, Lingle J, Hegerty J, Love R, Gounaris C, Zaremba S. Olanzapine compared with chlorpromazine in treatmentresistant schizophrenia. Am J Psychiatry 1998; 155(7):914-20. 27. Cordioli AV (ed) - Psicofármacos. Consulta rápida. 2ª ed. Artes Médicas, Porto Alegre, 2000. 28. Da Costa AR, Monzillo PH, Sanvito WL. Uso da clorpromazina no tratamento da cefaléia num serviço de emergências. Arq Neuropsiquiatr 1998; 56(3B):565-8. 29. Dahl SG, Hall H. Binding affinity of levomepromazine and two of its major metabolites of central dopamine and alphaadrenergic receptors in the rat. Psychopharmacology (Berl) 30. Dastidar SG, Jairaj J, Mookerjee M, Chakrabarty AN. Studies on antimicrobial effect of the antihistaminic phenothiazine trimeprazine tartrate. Acta Microbiol Immunol Hung 1997; 4(3):241-7. 31. Dastidar SG, Chakraborty P, Mookerjee M, Ganguly M, Chakrabarty AN. Studies on the existence of synergism between different antibiotics and a phenothiazine tranquilizer, promazine, possessing antimicrobial property. Acta Microbiol Immunol Hung 1994; 41(1):41-9. 32. Davidsen O, Lindeneg O, Walsh M. Analgesic treatment with levomepromazine in acute myocardial infarction. A randomized clinical trial. Acta Med Scand 1979; 205(3):191- 405. 3. Davis JR, Jennings RT, Beck BG, Bagian JP. Treatment efficacy of intramuscular promethazine for space motion sickness. Aviat Space Environ Med 1993; 64(3 Pt 1):230-3. 34. De Castro SL, Soeiro MN, De Meirelles M de N - Trypanosoma cruzi: effect of phenothiazines on the parasite and its interaction with host cells. Mem Inst Oswaldo Cruz 87(2):209-15, 1992. 35. DeGrandi T, Simon JE. Promethazine-induced dystonic reaction. Pediatr Emerg Care 1987; 3(2):91-2. 36. Delay J & Deniker P. 38 cas de psychoses traités par la cure prolongée et continué de 4568 RP. Ann Méd Psychol 1952; 110:364. 37. Delay J, Deniker P & Harl JM. Utilisation en thérapeutique psychiatrique d’une phénothiazine d’action centrale élective. Ann Méd Psychol 1952; 110(2), 112-117. 38. Denber HCB. Manual de Psicofarmacologia Clinica. Trad esp, Paidos, Buenos Aires, 1980.

Acta Paediatr Scand 1989; 78(1):131-2

39. Deodati F, Bec P, Labro JB, Arne JL, Chambon P. Maculopathy and levomepromazine. Bull Mem Soc Fr Ophtalmol 1973; 86(0):191-7. 40. Derby LE, Gutthann SP, Jick H, Dean AD. Liver disorders in patients receiving chlorpromazine or isoniazid. Pharmacotherapy 1993; 13(4):353-8. 41. Dollberg S, Hurvitz H, Kerem E, Navon P, Branski D. Hallucinations and hyperthermia after promethazine ingestion. 42. Eberlein-Konig B, Bindl A, Przybilla B. Phototoxic properties of neuroleptic drugs. Dermatology 1997; 194(2):131-5. 43. Eikmeier G. Priapism in neuroleptic therapy. Nervenarzt 1987; 58(12):771-2. 4. Engel H. Allergic agranulocytosis due to promethazine. Dtsch Med Wochenschr 1976; 101(30):1128-31. 45. Feinberg AP, Snyder SH. Phenothiazine drugs: structureactivity relationships explained by a conformation that mimics dopamine. Proc Natl Acad Sci U S A 1975; 72(5):1899-903. 46. Fernandez AR, Fretes R, Rubiales S, Lacuara JL, Paglini- Oliva P. Trypanocidal effects of promethazine. Medicina (B Aires) 1997; 57(1):59-63. 47. Filloux MC et al. Phenothiazine-induced acute colitis: a positive rechallenge case report. Clin Neuropharmacol 1999; 2(4): 244-5. 48. Fortes ZB, De Carvalho MH. Ensaio microbiológico de alguns derivados fenotiazínicos usando diferentes cepas de Bacillus subtilis. Rev Bras Pesqui Med Biol 1976; 9(4):183-6. 49. Fujisawa S, Kawabata S. Pharmaceutical studies on phenothiazine derivatives. VI. Photodegradation of methopromazine, levomepromazine, and its sulfoxide. Yakugaku Zasshi 1966; 86(6):514-21. 50. Garzotto N, Burti L, Tansella M. A fatal case of pancytopenia due to levomepromazine. Br J Psychiatry 1976; 129:443-5. 51. Ghosh N, Chattopadhyay U. Enhancement of immune response by phenothiazine administration in vivo. In Vivo 1993; 7(5):435-40. 52. Giacaman P, Andresen M, Gareca N, Bitran J, Dougnac A. Malignant neuroleptic syndrome, medical-psychiatric approach. Rev Med Chil 1997; 125(2):195-9. 53. Gillman PK. Successful treatment of serotonin syndrome with chlorpromazine. Med J Aust 1996; 165(6):345-6. 54. Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol 1998; 12(5):482-91. 5. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol 1999; 13(1):100-9. 56. Gobel H, Stadler T. Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine. Drugs 1997; 53 Suppl 2:34-9. 57. Gram LF, Hansen MG, Sindrup SH, Brosen K, Poulsen JH, Aaes-Jorgensen T, Overo KF. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 1993; 15(1):18-24. 58. Grinshpoon A, Berg Y, Mozes T, Mester R, Weizman A. Seizures induced by combined levomepromazine-fluvoxamine treatment. Int Clin Psychopharmacol 1993; 8(1):61-2. 59. Gusdon JP Jr. The treatment of erythroblastosis with promethazine hydrochloride. J Reprod Med 1981; 26(9):454- 8. 60. Hals PA, Hall H, Dahl SG. Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci 1988; 43(5):405-12. 61. Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos 1998; 26(6):536-9.

63. Hanel RA, Sandmann MC, Kranich M, De Bittencourt PR
56(4):833-7
Lippincott Williams & Wilkins, Filadélfia, 1999

62. Hamon J, Paraire J & Velluz J. Remarques sur l’action du 4560 RP sur l’agitation maniaque. Ann Méd Psychol 1952; 110(2): 331-335. Neuroléptico Maligno: relato de caso com recorrência associada com o uso de olanzapina. Arq Neuropsiquiatr 1998; 64. Harada T, Otsuki S, Sato M, Wake A, Fujiwara Y, Kashihara K, Fukuda K. Effectivity of zotepine in refractory psychoses: possible relationship between zotepine and nondopamine psychosis. Pharmacopsychiatry 1987; 20(1 Spec No):47-51. 65. Harden RN, Rogers D, Fink K, Gracely RH. Controlled trial of ketorolac in tension-type headache. Neurology 1998; 50(2):507-9. 6. Heinemann F, Assion HJ, Hermes G, Ehrlich M. Paroxetine-induced neuroleptic malignant syndrome. Nervenarzt 1997; 68(8):664-6. 67. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring symptoms of schizophrenia. Archives of General Psychiatry 1999; 56(1):29-36. 68. Hindmarch I, Shamsi Z, Stanley N, Fairweather DB. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol 1999; 48(2):200- 6. 69. Howanitz E, Pardo M, Smelson DA, Engelhart C, Einsenstein N, Stern RG & Losonczy MS. The Efficacy and Safety of Clozapine versus Chlorpromazine in Geriatric Schizophrenia. J Clin Psychiatry 1999; 60(1): 41-4. 70. Hu OY, Gfeller E, Perrin JH, Curry SH. Relative bioavailability of trimeprazine tablets investigated in man using HPLC with electrochemical detection. J Pharm Pharmacol 1986; 38(3):172-6. 71. Itoh T. Dose-related response of mouse mamma to some phenothiazine drugs. J Toxicol Sci. 1978 May;3(2):147-52. 72. Ito T, Koseki Y, Ando F, Saka M, Nakaya S.Proceedings: Acute and subacute toxicities of levomethiomeprazine. Jpn J Pharmacol. 1974;24(0):s:39. 73. Jackson SC, Walker JS. Self-administered intraurethral chlorpromazine: an unusual cause of priapism. Am J Emerg Med 1991; 9(2):171-5. 74. Janicak, PG. Handbook of Psychopharmacotherapy. 75. Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry 1999; 156(2):309-1. 76. John E. Promazine and neonatal hyperbilirubinaemia. Med J Aust 1975; 2(9):342-4. 7. Jones GR. Successful cancer therapy with promethazine: the rationale. Med Hypotheses 1996; 46(1):25-9. 78. Kane JM, Honigfeld G, Singer J, Meltzerd HY & the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: A double blind comparison with Chlorpromazine. Arch Gen Psychiat 1988; 45:789-796. 79. Kayed K, Hansen T, Godtlibsen OB. Controlled clinical investigation of trimeprazine as a sleep-inducer in normal subjects. Eur J Clin Pharmacol 1977; 1(3):163-7. 80. Keltner NL & Folks DG. Psychotropic Drugs. 2 ed, Mosby, St. Louis, 1997. 81. Kendra JR, Rugman FP, Flaherty TA, Myers A, Horsfield N, Barton A, Russell L. First use of G-CSF in chlorpromazineinduced agranulocytosis: a report of two cases. Postgrad Med J 1993; 69(817):885-7. 82. Kline NS. Use of Rauwolfia Serpentina Benth in neuropsychiatric conditions. Ann of N.Y. Acad of Sci 1954; 59, 107-132.

87(6):380-3

83. Kocian J. Advances in the pharmacotherapy of osteoporosis. Vnitr Lek 1995; 41(3):207-9. 84. Krinsky S et al. Sobre o emprego da reserpina em psiquiatria. Considerações preliminares. Arq Dep Assist Psicop Esta S Paulo 1955; 21:5-19. 85. Kristiansen JE, Mortensen I. Antibacterial effect of four phenothiazines. Pharmacol Toxicol 1987; 60(2):100-3. 86. Kristiansen JE, Vergmann B. The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria. Acta Pathol Microbiol Immunol Scand [B] 1986; 94(6):393-8. 87. Kubo N, Shirakawa O, Kuno T, Tanaka C. Antimuscarinic effects of antihistamines: quantitative evaluation by receptorbinding assay. Jpn J Pharmacol 1987; 43(3):277-82. 8. Laborit H, Huguenard P. L’Hibernation artificielle para moyens pharmacodynamiques et physiques. Press Méd 1951; 59: 1329. 89. Laborit H, Huguenard P & Alluaume R. Un nouveau stabilisateur végètatif (le 4560 RP). Presse Méd 1952; 60, 206-208. 90. Lal S, Bloom D, Silver B, Desjardins B, Krishnan B, Thavundayil J, Thompson T. Replacement of chlorpromazine with other neuroleptics: effect on abnormal skin pigmentation and ocular changes. J Psychiatry Neurosci 1993; 18(4):173-7. 91. Lal S, Nair NP. Is levomepromazine a useful drug in treatment-resistant schizophrenia? Acta Psychiatr Scand 1992; 85(3):243-5. 92. Lal S, Nair NP, Cecyre D, Quirion R. Levomepromazine receptor binding profile in human brain--implications for treatment-resistant schizophrenia. Acta Psychiatr Scand 1993; 93. Lamberth JL. Droperidol, ethyl isobutrazine and pethedine as premedicants for weaner pigs. Aust Vet J. 1968 Jul;4(7):3-4. 94. Le Borgne Y. On the effects of a new hypno-sedating, nonbarbituric agent, FH 040-3 in sleep disorders. J Med Bord 1967; 144(9):1356-8. 95. Lialiaris T, Pantazaki A, Sivridis E, Mourelatos D. Chlorpromazine-induced damage on nucleic acids: a combined cytogenetic and biochemical study. Mutat Res 1992; 265(2):155-63. 96. Lidsky TI, Yablonsky-Alter E, Zuck LG, Banerjee SP. Antipsychotic drug effects on glutamatergic activity. Brain Res 1997; 764(1-2):46-52. 97. Lucena J, Loreto G & Costa AS. Resultados do tratamento de doentes mentais pelo Amplictil. Neurobiologia 1956; 19(1- 2): 1-20. 98. Lundbeck Institute.Database. Disponível em w.luinst.org. 9. Madalena JC. Psicofarmacologia Clínica Básica. Fundo Editorial Byk-procienx. São Paulo, 1975. 100. Madsen F, Faurschou P, Banning AM, Engel AM, Sjogren P, Rosetzsky A. The protective effect of inhaled levomepromazine (Nozinan) on histamine-induced bronchial constriction. Pulm Pharmacol 1993; 6(2):129-36. 101. Markowitz JS, Wells BG, Carson WH. Interactions between antipsychotic and antihypertensive drugs. Ann Pharmacother 1995; 29(6):603-9. 102. Maxmen JS & Ward NG. Psicotrópicos. Consulta Rápida. Trad 2 ed, Artes Médicas, Porto Alegre, 1998. 103. McKelvey GM, Post EJ, Jeffery HE, Wood AK. Sedation with promethazine profoundly affects spontaneous airway protection in sleeping neonatal piglets. Clin Exp Pharmacol Physiol 1999; 26(1):920-6. 104. Meneghini CL, Angelini G. Elastotic and citrine skin following an allergic photo-contact dermatitis in a child. Contact Dermatitis 1975; 1(5):301-5. 105. Merville MP, Piette J, Decuyper J, Calberg-Bacq CM, van de Vorst A. Phototoxicity of phenothiazine derivatives. I.

(Parte 6 de 10)

Comentários